Does the use of proton pump inhibitors increase the risk of hypomagnesemia: An updated systematic review and meta-analysis.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
entrez:
29
3
2019
pubmed:
29
3
2019
medline:
5
4
2019
Statut:
ppublish
Résumé
Proton pump inhibitors (PPIs) are commonly used in the treatment of acid-related diseases; however, the association between the use of PPIs and potential risk of hypomagnesemia is controversial. In the present study, databases including PubMed, EMBASE, MEDLINE, PsycINFO, CINAHL, the Cochrane Library, and 4 Chinese databases were searched since the inception until April 2018. Previous observational studies on the incidence of hypomagnesemia in individuals exposed to PPIs were included. This systematic review involved 15 studies including 129,347 participants, and the sample size varied from 52 to 95,205. Meta-analysis of 14 studies indicated that the use of PPIs increased the risk of hypomagnesemia [RR, 1.44, 95% CI, 1.13-1.76; I, 85.2%]. Subgroup analysis revealed that the use of PPI was not associated with the incidence of hypomagnesemia in outpatients [RR, 1.49; 95% CI, 0.83-2.14; I, 41.4%] and hospitalized patients [RR, 1.05; 95% CI, 0.81-1.29; I, 62.1%], respectively. The use of PPIs was not related to the risk of hypomagnesemia based on the cut-off values of 1.8 mg/dL [RR, 1.73; 95% CI, 0.87-2.58; I, 65.2%], 1.7 mg/dL [RR, 1.48; 95% CI, 0.90-2.06; I, 87.6%], and 1.6 mg/dL [RR, 0.98; 95% CI, 0.69-1.27; I, 67.9%]. The association between the exposure to PPI and the incidence of hypomagnesemia remained unclear. Due to the remarkable heterogeneity in previous studies, a definitive conclusion could not be drawn. Further research should be conducted to investigate the relationship between the use of individual PPI and potential risk of hypomagnesemia, and a dose-response analysis may be required.
Sections du résumé
BACKGROUND
BACKGROUND
Proton pump inhibitors (PPIs) are commonly used in the treatment of acid-related diseases; however, the association between the use of PPIs and potential risk of hypomagnesemia is controversial.
METHODS
METHODS
In the present study, databases including PubMed, EMBASE, MEDLINE, PsycINFO, CINAHL, the Cochrane Library, and 4 Chinese databases were searched since the inception until April 2018. Previous observational studies on the incidence of hypomagnesemia in individuals exposed to PPIs were included.
RESULTS
RESULTS
This systematic review involved 15 studies including 129,347 participants, and the sample size varied from 52 to 95,205. Meta-analysis of 14 studies indicated that the use of PPIs increased the risk of hypomagnesemia [RR, 1.44, 95% CI, 1.13-1.76; I, 85.2%]. Subgroup analysis revealed that the use of PPI was not associated with the incidence of hypomagnesemia in outpatients [RR, 1.49; 95% CI, 0.83-2.14; I, 41.4%] and hospitalized patients [RR, 1.05; 95% CI, 0.81-1.29; I, 62.1%], respectively. The use of PPIs was not related to the risk of hypomagnesemia based on the cut-off values of 1.8 mg/dL [RR, 1.73; 95% CI, 0.87-2.58; I, 65.2%], 1.7 mg/dL [RR, 1.48; 95% CI, 0.90-2.06; I, 87.6%], and 1.6 mg/dL [RR, 0.98; 95% CI, 0.69-1.27; I, 67.9%].
CONCLUSION
CONCLUSIONS
The association between the exposure to PPI and the incidence of hypomagnesemia remained unclear. Due to the remarkable heterogeneity in previous studies, a definitive conclusion could not be drawn. Further research should be conducted to investigate the relationship between the use of individual PPI and potential risk of hypomagnesemia, and a dose-response analysis may be required.
Identifiants
pubmed: 30921222
doi: 10.1097/MD.0000000000015011
pii: 00005792-201903290-00048
pmc: PMC6456119
doi:
Substances chimiques
Proton Pump Inhibitors
0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15011Références
Kidney Res Clin Pract. 2015 Jun;34(2):98-102
pubmed: 26484029
Curr Opin Endocrinol Diabetes Obes. 2014 Feb;21(1):3-8
pubmed: 24310148
Pharmacoepidemiol Drug Saf. 2012 May;21(5):553-9
pubmed: 22337212
Am J Kidney Dis. 2013 Oct;62(4):730-7
pubmed: 23664547
Turk J Gastroenterol. 2017 Mar;28(2):104-109
pubmed: 28082254
Int J Gen Med. 2013 Jun 28;6:515-8
pubmed: 23847429
Am J Med. 2011 Jun;124(6):519-26
pubmed: 21605729
Am Heart J. 1998 Sep;136(3):480-90
pubmed: 9736141
Rev Assoc Med Bras (1992). 2013 May-Jun;59(3):276-9
pubmed: 23680271
J Nephrol. 2014 Dec;27(6):707-11
pubmed: 24816563
J Clin Pharmacol. 2014 Aug;54(8):889-95
pubmed: 24771616
Am J Kidney Dis. 2015 Nov;66(5):775-82
pubmed: 26123862
Drugs. 2008;68(7):925-47
pubmed: 18457460
Aliment Pharmacol Ther. 2007 Aug 15;26(4):545-53
pubmed: 17661758
Dig Dis Sci. 2011 Apr;56(4):931-50
pubmed: 21365243
Kidney Int. 2013 Apr;83(4):692-9
pubmed: 23325090
Ren Fail. 2015 Aug;37(7):1237-41
pubmed: 26108134
Eur J Intern Med. 2016 May;30:99-103
pubmed: 26905320
Am J Ther. 2015 Jan-Feb;22(1):14-21
pubmed: 23846522
PLoS One. 2015 Nov 30;10(11):e0143656
pubmed: 26618538
Arch Intern Med. 2010 May 10;170(9):784-90
pubmed: 20458086
Mol Pharm. 2012 Dec 3;9(12):3495-505
pubmed: 23051182
J Gastroenterol Hepatol. 2018 Oct;33(10):1717-1721
pubmed: 29514412
Bone Marrow Transplant. 2014 Aug;49(8):1106-8
pubmed: 24820219
PLoS One. 2014 Nov 13;9(11):e112558
pubmed: 25394217
JAMA. 2009 May 27;301(20):2120-8
pubmed: 19470989
Int J Clin Pract. 2014 Nov;68(11):1352-7
pubmed: 24898571
Am J Nephrol. 2014;39(3):204-9
pubmed: 24577494
Am J Clin Nutr. 2013 Jul;98(1):160-73
pubmed: 23719551